此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

一项在激素受体阳性早期乳腺癌绝经后女性中比较注射用依西美坦SIE与口服依西美坦稳态生物利用度的研究 (SIE-1)

2026年10月8日 更新者：Rovi Pharmaceuticals Laboratories

一项开放标签、单序列研究，旨在评估接受内分泌治疗的激素受体阳性早期乳腺癌绝经后女性中，每季度使用来曲唑SIE与每日一次口服2.5 mg来曲唑（弗隆®）的稳态生物利用度比较。(SIE-1)

The study aims to compare the amount of the drug letrozole that gets into the bloodstream after multiple doses of the quarterly injection Letrozole SIE, versus multiple doses of the standard oral daily tablet of letrozole (Femara®), in women who have gone through menopause and have received treatment for hormone receptor-positive early breast cancer. Participants must have completed at least five years of hormone therapy with at least two of those years with letrozole before starting their participation in the study. Women who have completed four years of hormone therapy are also eligible if their doctor considers them at low risk of cancer returning.

研究概览

地位

招聘中

条件

干预/治疗

详细说明

The primary objective of the study is to evaluate the steady-state comparative bioavailability of quarterly injectable Letrozole SIE compared to United States (US)-sourced oral Femara® in the US-sourced arm and of quarterly injectable Letrozole SIE compared to European Union (EU)-sourced oral Femara® in the EU-sourced arm, in post-menopausal women treated with endocrine therapy for hormone-receptor positive (HR+) early breast cancer (EBC). The study also aims to characterize the elimination phase of Letrozole SIE after multiple doses.

The study consists of four periods: Screening, Treatment Period 1 (TP1), Treatment Period 2 (TP2) and Extension Period. After the Screening Period, participants will be randomized to two different arms: US-sourced oral Femara® or EU-sourced oral Femara® for 14 days to achieve the steady-state concentrations of letrozole in TP1. After receiving the latest oral letrozole dose, participants from both arms will start TP2. In TP2, quarterly injectable Letrozole SIE will be administered to achieve steady-state. After TP2, a subset of participants (up to 60 participants, regardless of which study arm they belong to) will continue in the study for the assessment of the elimination phase of Letrozole SIE after multiple doses during the Extension Period.

It is estimated that approximately 120 subjects should be randomized.

研究类型

介入性

注册 (估计的)

120

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 塞尔维亚
      • Belgrade、塞尔维亚、11000
        • 招聘中
        • Investigational Site number SRB-004
      • Belgrade、塞尔维亚、11080
        • 招聘中
        • Investigational Site number SRB-002
      • Kamenitz、塞尔维亚、21204
        • 招聘中
        • Investigational Site number SRB-001
      • Kragujevac、塞尔维亚、34000
        • 招聘中
        • Investigational Site number SRB-003
      • Niš、塞尔维亚、18000
        • 招聘中
        • Investigational Site number SRB-005
  • 美国
    • California
      • Beverly Hills、California、美国、90212
        • 招聘中
        • Precision NextGen Oncology and Research Center (Investigational Site number USA-001)
    • Florida
      • Margate、Florida、美国、33063
        • 招聘中
        • D&H National Research Centers INC (Investigational Site number USA-002)
      • Port Orange、Florida、美国、32127
        • 招聘中
        • United Medical Research (Investigational Site number USA-005)
  • 西班牙
      • Alcorcón、西班牙、28922
        • 招聘中
        • Hospital Universitario Fundación Alcorcón (Investigational Site number ESP-015)
      • Barcelona、西班牙、08023
        • 招聘中
        • NEXT Oncology. Phase I Unit / IOB - Hospital Quironsalud Barcelona (Investigational Site number ESP-002)
      • Granada、西班牙、18014
        • 招聘中
        • Hospital Universitario Virgen de las Nieves (Investigational Site number ESP-011)
      • Jaén、西班牙、23007
        • 招聘中
        • Hospital Universitario de Jaén (HUJ) (Investigational Site number ESP-005)
      • León、西班牙、24071
        • 招聘中
        • Complejo Asistencial Universitario de León - Hospital de León (Investigational Site number ESP-013)
      • Lleida、西班牙、25198
        • 招聘中
        • Hospital Universitario Arnau de Vilanova de Lleida (Investigational Site number ESP-003)
      • Manresa、西班牙、08243
        • 招聘中
        • Althaia Xarxa Assistencial Universitària de Manresa F.P (Investigational Site number ESP-012)
      • Murcia、西班牙、30120
        • 招聘中
        • Hospital Clínico Universitario Virgen de la Arrixaca (Investigational Site number ESP-009)
      • Málaga、西班牙、29004
        • 招聘中
        • Hospital Quirónsalud Málaga (Investigational Site number ESP-001)
      • Pozuelo de Alarcón、西班牙、28223
        • 招聘中
        • NEXT Oncology Phase I Unit - Hospital Universitario Quironsalud Madrid (Investigational Site number ESP-008)
      • Reus、西班牙、43204
        • 招聘中
        • Hospital Universitari Sant Joan de Reus (Investigational Site number ESP-004)
      • Sabadell、西班牙、08208
        • 招聘中
        • Consorci Corporació Sanitària Parc Taulí - Hospital de Sabadell (Investigational Site number ESP-006)
      • Santiago de Compostela、西班牙、15705
        • 招聘中
        • Hospital Clinico Universitario Santiago de Compostela (Investigational Site number ESP-007)

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 80年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Women with weight of ≥50 kg and a Body Mass Index (BMI) ≥19 kg/m2 and ≤39 kg/m2
  • Postmenopausal women.
  • Women with confirmed diagnosis of HR+/HER2- or HR+/HER2+ early stage breast cancer who have completed at least 5 years of endocrine therapy, at least 2 years of which were with letrozole. Participants at a low risk of relapse, as assessed by the investigator, can also be eligible after completing 4 years of adjuvant endocrine therapy, at least 2 of which were with letrozole.
  • Women in good health.
  • Women who have undergone breast imaging per applicable guidelines (e.g., mammogram) within the last 12 months with no evidence of malignancy (documentation required), and if not done, must be willing to have 1 performed prior to baseline.

Exclusion Criteria:

  • Presence of an uncontrolled, unstable, clinically significant medical condition.
  • Have used estrogen or progesterone systemic or topical therapy, oral contraceptives, androgens, LH-releasing hormone analogs, prolactin inhibitors, or antiandrogens within 3 months prior to screening.
  • Use of inducers or inhibitors of CYP3A4 and CYP2A6.
  • Diagnosed with osteoporosis.
  • Preexisting cardiovascular disease
  • Positive result for hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, or HIV antibodies.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：美国原产口服弗隆®
药品：US-sourced oral Femara® + Letrozole SIE

US-sourced Femara® 2.5 mg/day oral for 14 days (treatment period 1) + quarterly injectable Letrozole SIE (treatment period 2)
实验性的：欧盟来源的口服弗隆®
药品：EU sourced oral Femara® + Letrozole SIE

EU-sourced oral Femara® 2.5 mg/day for 14 days (treatment period 1) + quarterly injectable Letrozole SIE (treatment period 2)

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Area under the concentration-time curve within a dosing interval at Steady-State (SS AUCtau)
大体时间：After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® on Day 14 TP1

Individual and mean area under the concentration-time curve within a dosing interval at steady-state
After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® on Day 14 TP1

次要结果测量

结果测量
措施说明
大体时间
Adverse Events
大体时间：From the time of obtaining signed informed consent until the final follow-up visit on Day 281 (or Day 421 for the subset of participants in the Extension Period)

Incidence of adverse events (type, severity, seriousness, and relationship to study drug), including the incidence of treatment-emergent adverse events (TEAEs), the incidence of serious TEAEs, and the incidence of TEAEs leading to treatment discontinuation.
From the time of obtaining signed informed consent until the final follow-up visit on Day 281 (or Day 421 for the subset of participants in the Extension Period)
Injection site reactions
大体时间：At pre-dose and 1 hour after each Letrozole SIE administration in TP2

Incidence of injection site reactions
At pre-dose and 1 hour after each Letrozole SIE administration in TP2
Injection-related pain score
大体时间：From baseline TP2 to the follow-up visit on Day 281

Changes in injection-related pain score by numeric rating scale (NRS). The NRS evaluates the intensity of injection-related pain experienced at the time of Letrozole SIE administration. It is scored from 0 to 10 (0 meaning no pain and 10 meaning the worst possible pain).
From baseline TP2 to the follow-up visit on Day 281
Bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA)
大体时间：From screening to Day 281 TP2

Changes in bone mineral density BMD by DXA
From screening to Day 281 TP2
Average plasma drug concentration during a dosing interval at Steady-State (SS Cave)
大体时间：After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1

Individual and mean steady-state average plasma drug concentration during a dosing interval
After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1
Minimum drug concentration at steady-state (Cmin ss)
大体时间：After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1

Minimum drug concentration at steady-state
After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1
Maximum plasma concentration at steady-state (Cmax ss)
大体时间：After multiple doses of Letrozole SIE at Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1

Maximum plasma concentration at steady-state
After multiple doses of Letrozole SIE at Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1
Letrozole blood level percent fluctuation
大体时间：After multiple doses of Letrozole SIE at Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1

Individual and mean letrozole blood percent fluctuation
After multiple doses of Letrozole SIE at Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1
Time to peak observed concentration (Tmax)
大体时间：After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1

Time to peak observed concentration
After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1
Steady-State (SS)
大体时间：After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1

Characterization of the steady-state
After multiple doses of Letrozole SIE until Day 281 TP2 and after multiple doses of US-sourced oral Femara® or EU-sourced oral Femara® at Day 14 TP1
Terminal rate constant (λz)
大体时间：After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period

Individual and mean Terminal rate constant (λz) after multiple doses of Letrozole SIE in the subset of participants in the Extension Period
After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period
Terminal half-life (t1/2)
大体时间：After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period

Individual and mean Terminal half-life after multiple doses of Letrozole SIE in the subset of participants in the Extension Period
After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period
Area under the curve extrapolated to infinity (AUC∞)
大体时间：After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period

Individual and mean Area under the curve extrapolated to infinity after multiple doses of Letrozole SIE in the subset of participants in the Extension Period
After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period
Area under the curve that is extrapolated (AUCextrap)
大体时间：After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period

Percentage of area under the curve that is extrapolated after multiple doses of Letrozole SIE in the subset of participants in the Extension Period
After multiple doses of Letrozole SIE in TP2 until Day 421 in the Extension Period

其他结果措施

结果测量
措施说明
大体时间
Hormone supression
大体时间：From screening to the final follow-up visit on Day 281 (or Day 421 for the subset of participants in the Extension Period)

Analysis of letrozole exposure and hormone suppression measuring the sex hormone estrone (E1), sulfate estrone (SE1), and estradiol (E2) plasma levels.
From screening to the final follow-up visit on Day 281 (or Day 421 for the subset of participants in the Extension Period)
CYP2A6 genotyping
大体时间：From screening to final follow-up visit Day 281 (or Day 421 for the subset of participants in the Extension Period)

Proportion of participants in each CYP2A6 metabolizer phenotype category (normal, intermediate, slow)
From screening to final follow-up visit Day 281 (or Day 421 for the subset of participants in the Extension Period)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Rovi Pharmaceuticals Laboratories

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月8日

初级完成 (估计的)

2028年5月1日

研究完成 (估计的)

2028年10月1日

研究注册日期

首次提交

2026年1月22日

首先提交符合 QC 标准的

2026年2月3日

首次发布 (实际的)

2026年2月10日

研究记录更新

最后更新发布 (实际的)

2026年10月9日

上次提交的符合 QC 标准的更新

2026年10月8日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • ROV-SIE-2025-01
  • 2025-523269-31-00 (克蒂斯)
  • 2025 (美国 NIH 拨款/合同)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅